20221027104337.jpg)
20221027104337.jpg&width=400&height=400)
Yale Cancer Center (YCC) experts will present at the 2025 American Association of Cancer Research (AACR) Annual Meeting, which kicks off this Friday in Chicago at the McCormick Place Convention Center. As one of the largest global gatherings of cancer experts, the meeting will highlight new cancer treatments and practice-changing clinical trials from around the world.
The Yale research, published in Science Signaling on March 25, offers new findings that could help improve therapies for glioblastoma and other aggressive cancers that are difficult to treat.
Nurses from Yale New Haven Health鈥檚 Smilow Cancer Hospital (SCH) will showcase their latest research from April 9鈥�13 at the 50th Annual Congress of the Oncology Nursing Society (ONS) in Denver, Colo. ONS, a professional organization comprising of more than 35,000 healthcare professionals, hosts this international event for nursing oncology professionals to exchange knowledge and advance the field of cancer care.
Yale Department of Surgery oncologists and trainees at Yale Cancer Center will present new findings at the Society of Surgical Oncology (SSO) Annual Meeting in Tampa, Fla., from March 27鈥�29. The conference focuses on improving surgical cancer care for patients through educational sessions as well as oral and poster presentations for surgical oncologists, researchers, and patient advocates.
A new study led by Dr. Roy Herbst, deputy director of Yale Cancer Center, found evidence to support the value of a tool that measures the presence of cancer-derived molecules in the blood of patients with lung cancer, years after their treatment.
The study co-led by Dr. Elizabeth Claus of Yale Cancer Center showed an increased presence of haloalkane-associated mutational signatures in the firefighters鈥� tumors.
Mehra Golshan, MD, MBA, a professor of surgery at Yale School of Medicine and executive vice chair in the Department of Surgery, will be awarded a 2025 Ellis Island Medal of Honor from the Ellis Island Honors Society. The medal recognizes Golshan鈥檚 contributions to breast cancer treatment and research, his dedication to patient care, and his commitment to mentorship.
Personalized cancer vaccines (PCVs) train the body鈥檚 immune system to recognize and destroy a threat. In this trial, all nine patients who received multiple doses of the vaccine had an immune response within a three-week period and cancer fighting T cells remained elevated for the duration of the study and for years afterward.
Metastatic clear cell renal cell carcinoma (mccRCC), an aggressive type of kidney cancer, historically has presented limited treatment options. Immune checkpoint inhibitors, a form of immunotherapy, can lead to exceptional, durable responses (when the tumor substantially shrinks for a very long period of time) for some patients with mccRRC, allowing them to live longer with a better quality of life.
Severe hemophilia A is a genetic disorder that prevents blood from clotting properly, posing a constant risk of dangerous bleeding episodes. Infants with severe hemophilia A (HA) are at risk of brain bleeds, which can lead to serious long-term brain damage. Emicizumab (Hemlibra) was approved by the FDA in 2018 to prevent and reduce bleeding for patients who suffer from hemophilia A.
Yale researchers made an unexpected discovery鈥攖urncoat T cells that help a tumor evade other cancer-fighting immune T cells鈥攊n a study of patients living with advanced melanoma that was published Nov. 28 in Nature Immunology.
Yale Cancer Center (YCC) researchers at Yale School of Medicine will present new research at the 66th annual American Society of Hematology (ASH) annual meeting in San Diego, Calif., December 7-10. Known as 鈥渢he premier event in classical and malignant hematology鈥�, the ASH meeting includes oral and poster presentations, as well as workshops and educational sessions for hematology professionals and advocates.
Yale Cancer Center (YCC) researchers at Yale School of Medicine will present new research at the 47th annual San Antonio Breast Cancer Symposium (SABCS) at the Henry B. Gonzalez Convention Center from December 10 to 13.
Prostate cancer is the second most commonly diagnosed cancer in men (behind skin cancer), with varying levels of aggressiveness. It鈥檚 also the second leading cause of cancer death, behind only lung cancer. A new study led by Yale Cancer Center researchers at Yale School Medicine found a substantial increase in the adoption of active surveillance (AS) and watchful waiting (WW) treatment strategies over the past decade 鈥� an encouraging trend for men seeking less invasive treatment options.
William K. Oh, MD, has been appointed as Medical Director of Smilow Cancer Hospital at Greenwich Hospital, as well as Director of Precision Medicine for Yale Cancer Center and Smilow Cancer Hospital.
A new study led by Yale Cancer Center researchers at Yale School of Medicine titled, "Living Flat: Stories from Women of Color After Mastectomy," explains how cultural factors, spirituality, and personal beliefs play an important role in the lives of women of color after mastectomies.
Dr. David Braun, a medical oncologist at Yale Cancer Center, will be awarded the Christopher G. Wood Rising Star Award by the Kidney Cancer Association at November's International Kidney Cancer Symposium.
Significantly more younger people underwent colorectal cancer screening after the recommended age to begin such screening was lowered, Yale researchers report. In a new study of 10 million insured people aged 45 to 49, researchers found that a recommendation by the United States Preventative Services Task Force to drop the age for starting colorectal cancer screening by five years to age 45 was highly effective 鈥� tripling the rate of screening overall 鈥� but the magnitude of increase was significantly smaller for low-income and rural populations.
A new pathology tool created at Yale harnesses barcode technology and shows potential for use in cancer diagnoses. The technology, Patho-DBiT (pathology-compatible deterministic barcoding in tissue), was discussed in a new study that published Sept. 30 in the journal Cell. Co-corresponding author Dr. Mina Xu, a Yale Cancer Center (YCC) member, professor of pathology at Yale School of Medicine (YSM), and the YSM director of hematopathology, shared her enthusiasm for the new tool.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal 麻豆传媒 keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right